NIFTY 50

Sanford Bernstein prefers Cipla, Sun Pharma & Lupin in the pharma space

Updated : March 02, 2021 11:01 AM IST

Nithya Balasubramanian, director of Sanford Bernstein said that she likes Cipla and Sun Pharmaceutical Industries in the pharma space.

Speaking in an interview to CNBC-TV18, she said, “Since the start of the year Cipla and Sun are the top picks, Cipla largely because we like the increasing visibility into their respiratory generics pipeline and the reason we like Sun because it has become more constructive about specialty portfolio. We thing the specialty portfolio can turn around and that is broadly why we like Sun Pharma.”

She also likes Lupin and has an outperform rating on the stock due to their complex generics pipeline in the US.

"I think Lupin is as invested in the complex respiratory generics pipeline as Cipla is,” she said.

We also like the fact that Lupin has built capabilities in the biosimilar space, Balasubramanian added.

For more details, watch the video
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV

recommended for you